Abstract |
Hairy cell leukemia (HCL) is a rare B-cell lymphoproliferative disorder, but is gratifying to treat for both physicians and patients. During the 50 years since its initial description as a clinical entity, hematologists have been fascinated by the bizarre appearance of the malignant cell with its hair-like projections. Therapeutic strategies have evolved from splenectomy to interfere to the purine analogues which have become the treatments of-choice and are very effective. Immunoconjugate Therapy with BL22 (anti-CD22 [corrected] antibody linked to truncated to Pseudomonas exotoxin) represents the newest milestone in the development of effective treatment for hairy cell leukemia.
|
Authors | Martin S Tallman, Aaron Polliack |
Journal | Leukemia & lymphoma
(Leuk Lymphoma)
Vol. 50 Suppl 1
Pg. 2-7
(Oct 2009)
ISSN: 1029-2403 [Electronic] United States |
PMID | 19814690
(Publication Type: Historical Article, Journal Article, Review)
|
Chemical References |
|
Topics |
- Combined Modality Therapy
- History, 20th Century
- History, 21st Century
- Humans
- Immunoconjugates
(therapeutic use)
- Leukemia, Hairy Cell
(drug therapy, surgery)
- Medical Oncology
(history, methods, trends)
- Purines
(antagonists & inhibitors, therapeutic use)
- Splenectomy
- Treatment Outcome
|